Axsome Therapeutics INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersNew York, NY
US patents127
SAM.gov UEIKGMGGVWRZRW4
CAGE code7J7H1
Incorporated inDE
LEI549300EXGR0XLRJEIB95
- treatments
- depression
- s Disease Agitation
- developing
- AXS-05
- AXS-12
- AXS-14
Named on the company’s own website, read JUL 29, 2026
Open positions
Openings read from Axsome Therapeutics INC’s own job board on Greenhouse, last checked NOV 20, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Specialty Account Manager, Long Term Care (Roanoke, VA)Roanoke, VA · Field Sales · posted NOV 17, 2026
- Specialty Account Manager, Symbravo (Grand Rapids, MI)Grand Rapids, MI · Field Sales · posted NOV 16, 2026
- Specialty Account Manager, Symbravo (Toledo, OH)Toledo, OH · Field Sales · posted NOV 16, 2026
- Specialty Account Manager, Symbravo (Chattanooga, TN)Chattanooga, TN · Field Sales · posted NOV 12, 2026
- Senior Regional Marketer, Neurology (East Region)Axsome Therapeutics INC · New York, NY · Marketing · posted NOV 12, 2026
- Specialist, Quality ControlAxsome Therapeutics INC · New York, NY · Quality · posted NOV 10, 2026
- Associate, Marketing OperationsAxsome Therapeutics INC · New York, NY · Marketing · posted NOV 9, 2026
- Senior Regional Marketer, Neurology (West Region)Los Angeles, CA · Marketing · posted NOV 6, 2026
- Senior Manager, Data ManagementAxsome Therapeutics INC · New York, NY · Clinical Research & Operations · posted NOV 6, 2026
- Associate Director, Clinical Trial RecruitmentAxsome Therapeutics INC · New York, NY · Clinical Research & Operations · posted NOV 6, 2026
94 more on the company’s board
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
127 US patents granted 2017–2025, 82 of them in the five years to SEP 2025.
Pharmaceuticals 127
- Pharmaceutical compositions comprising meloxicamUS 12,370,196 · granted JUL 29, 2025
- Pharmaceutical compositions comprising bupropion and cysteineUS 12,357,697 · granted JUL 15, 2025
- Pharmaceutical compositions comprising meloxicamUS 12,357,640 · granted JUL 15, 2025
- Pharmaceutical compositions comprising a tolfenamic acidUS 12,268,693 · granted APR 8, 2025
- Use of reboxetine to treat narcolepsyUS 12,246,023 · granted MAR 11, 2025
Newest 5 shown · Granted to Axsome Therapeutics, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Axsome Therapeutics INC | New York | NY | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


